Vaxil BioVXLLF 36 ROC (Joel Greenblatt) % is -1,620.51% as of Mar. 2026. GuruFocus rates VXLLF with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,321 Biotechnology companies, Vaxil Bio ranks worse than 71.61% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Vaxil Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,620.51%.
The historical rank and industry rank for Vaxil Bio's ROC (Joel Greenblatt) % or its related term are showing as below:
VXLLF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -29200 Med: -2482.59 Max: -1156.67
Current: -1432.26
During the past 13 years, Vaxil Bio's highest ROC (Joel Greenblatt) % was -1156.67%. The lowest was -29200.00%. And the median was -2482.59%.
VXLLF's ROC (Joel Greenblatt) % is ranked worse than 71.61% of 1321
companies
in the Biotechnology industry
Industry Median: -296.6
vs VXLLF: -1432.26
Vaxil Bio's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Vaxil Bio (OTCPK:VXLLF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for Vaxil Bio's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VXLLF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Vaxil Bio's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaxil Bio ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaxil Bio's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vaxil Bio's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -1,620.51% mean?
Vaxil Bio (VXLLF) has a ROC (Joel Greenblatt) % of -1,620.51% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vaxil Bio and its competitors. According to the industry distribution chart, Vaxil Bio ranks #946 out of 1321 companies in the Biotechnology industry, placing it in the top 71.6%.
Is Vaxil Bio's ROC (Joel Greenblatt) % too high?
Vaxil Bio's current ROC (Joel Greenblatt) % is -1,620.51%. Based on the distribution chart, Vaxil Bio ranks #946 out of 1321 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vaxil Bio has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vaxil Bio ranks #946 out of 1321 companies for ROC (Joel Greenblatt) %. This places Vaxil Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vaxil Bio and its competitors. Vaxil Bio's current ROC (Joel Greenblatt) % is -1,620.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current ROC (Joel Greenblatt) % of -1,620.51%. The current ROC (Joel Greenblatt) % is -1,620.51%. Vaxil Bio's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current ROC (Joel Greenblatt) % is -1,620.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
36GF Score
Get the complete analysis for VXLLF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VXLLF has been successfully added to your 
